Overview A Phase 2a Study of LAM-001 for the Treatment of PH Status: Not yet recruiting Trial end date: 2025-02-28 Target enrollment: Participant gender: Summary This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension. Phase: Phase 2 Details Lead Sponsor: AI Therapeutics, Inc.